Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments.
Eighty-seven consecutive patients with metastatic breast cancer were treated with aminoglutethimide plus hydrocortisone. All patients were postmenopausal and had progressive disease following prior chemotherapy and endocrine therapy. Eighty-five women were evaluable for drug response. One patient showed complete remission and 14 patients partial response, for an overall response rate of 17%. The median duration of response was 11+ months. The response rate was highest in the presence of soft tissue involvement (36%). The most common side effects were transient skin rash, lethargy, and dizziness. Two patients discontinued treatment because of cutaneous allergy. Aminoglutethimide can be considered a moderately active agent when utilized as second- or third-line hormonal therapy.
Zambetti
M
M
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
Brambilla
C
C
Tancini
G
G
Bonadonna
G
G
D000315:Adrenalectomy; D000328:Adult; D000368:Aged; D000616:Aminoglutethimide / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D008593:Menopause; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000032:analysis; D013629:Tamoxifen / Q000627:therapeutic use
D011960:Receptors, Estrogen; D013629:Tamoxifen; D000616:Aminoglutethimide; D006854:Hydrocortisone